TONIX Presentation November 2011

Corporate Presentation November 2011

Disclosures ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Pharmaceuticals Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Experienced Leadership Management Team Seth Lederman, MD Founder, CEO, Chairman Co-founder, Vela, Targent, Validus, Fontus Benjamin Selzer Chief Operating Officer Aton, Reliant, investment banking (Lehman Brothers & Banc of America Securities) Rhonda Rosen, CPA Chief Financial Officer CFO, Validus, Fontus , two divisions of CIGNA , PricewaterhouseCoopers

Accomplished Independent Board Board of Directors

Fibromyalgia Market Opportunity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* National Institutes of Health, U.S. Department of Health and Human Services ** Source: Frost & Sullivan Fibromyalgia Market Study, December 2010

Fibromyalgia: Vicious Cycle ,[object Object],[object Object],TNX-102 Pain Lyrica Sleep Disturbance No approved medications Depressed Mood Cymbalta

Comparison of Fibromyalgia Drugs Approved Treatments Pipeline Treatments * Jazz recently announced they are discontinuing the development of Rekinla ,[object Object],[object Object]

Cyclobenzaprine Has an Impressive Safety Record and is Widely Used ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* Source: Frost & Sullivan Fibromyalgia Market Study, December 2010

VLDC FM Pilot Study Results: Symptom Measures * Change from Baseline (week 8): tenderness measured by dolorimetry; HAD is the Hospital Anxiety and Depression Scale; HAD Depression is the HAD depression subscale 0% * Moldofsky et al., J. Rheum. December 2011: http://jrheum.org/content/early/2011/08/30/jrheum.110194.full.pdf+html ,[object Object],[object Object]

TNX-102: VLDC New Formulation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TNX-102: Development Plan ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TNX-102: Compelling Risk / Reward Profile ,[object Object],Risk Factor Commentary FDA Risk - Safety ,[object Object],[object Object],[object Object],[object Object],FDA Risk - Efficacy ,[object Object],[object Object],Commercial Risk ,[object Object],[object Object],[object Object],Reimbursement Risk ,[object Object],[object Object],Generic Competition ,[object Object],[object Object]

TNX-102: Compelling Risk / Reward Profile ,[object Object],[object Object],[object Object],[object Object]

TNX-105: VLDC for PTSD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* National Institutes of Mental Health & National Institutes of Health

FM & PTSD - Related Conditions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Pharmaceuticals Pipeline ,[object Object],Product Indication Status TNX-102 Fibromyalgia ,[object Object],[object Object],[object Object],[object Object],TNX-105 Post-Traumatic Stress Disorder ,[object Object],[object Object],[object Object],[object Object],TNX-201 Headache ,[object Object],[object Object],[object Object],TNX-301 Alcoholism ,[object Object],[object Object]

Exclusivity & Patents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Upcoming Milestones ,[object Object],Timing Milestones Related to TNX-102 December 2011 ,[object Object],Jan-Feb 2012 ,[object Object],Q1 2012 ,[object Object],Q3 2012 ,[object Object],Q1 2013 ,[object Object],Q2-Q3 2013 ,[object Object],[object Object]

Why Invest in TONIX? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TONIX Presentation November 2011

Recommended

Recommended

More Related Content

Similar to TONIX Presentation November 2011

Similar to TONIX Presentation November 2011 (20)

Recently uploaded

Recently uploaded (20)

TONIX Presentation November 2011